Sugi Predict

Sugi Predict / Compounds / SCHEMBL6199839

SCHEMBL6199839

SCHEMBL6199839

COC(=O)[C@@H]1C[C@@H](OC)CN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSC P53634 1/20 0.42
▸ CHRNB2 P17787 2/20 0.41
▸ CHRNA4 P43681 2/20 0.41
▸ CHRNB4 P30926 1/20 0.41
▸ CHRNA3 P32297 1/20 0.41
▸ CHRNA7 P36544 1/20 0.41
▸ PIM1 P11309 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ CHEK2 O96017 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10151348 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL3834619 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL5605655 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL13403384 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL11449583 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL7021231 1.00 CTSC (0.42) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL7321357 0.98 CTSC (0.41) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL7321361 0.98 CTSC (0.41) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL3554623 0.98 CTSC (0.41) CTSCCHRNB2CHRNA4CHRNB4CHRNA3
Hydrochloric Acid SCHEMBL3554626 0.98 CTSC (0.41) CTSCCHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 — — US disclosed
US-12325701-B2 YKL-40 inhibitors and their therapeutic MOLECURE S.A. (PL) 2025-06-10 — — US disclosed
US-20250059163-A1 FUSED RING COMPOUNDS GENENTECH INC (US) 2025-02-20 — — US disclosed
EP-4483881-A2 FUSED RING COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-01-01 — — EP disclosed
WO-2024235121-A1 FUSED RING COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-11-21 — — WO disclosed
EP-3735299-B1 FUSED RING COMPOUNDS HOFFMANN LA ROCHE (CH) 2024-10-02 — — EP disclosed
US-12084429-B2 Fused ring compounds GENENTECH, INC. (US) 2024-09-10 — — US disclosed
CN-118084866-A Condensed ring compound 豪夫迈·罗氏有限公司 2024-05-28 — — CN disclosed
CN-118084870-A Condensed ring compound 豪夫迈·罗氏有限公司 2024-05-28 — — CN disclosed
CN-118084867-A Condensed ring compound 豪夫迈·罗氏有限公司 2024-05-28 — — CN disclosed
US-8343968-B2 Case of renin inhibitors MERCK CANADA INC. (CA) 2013-01-01 — — US disclosed
US-20110123496-A1 BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-05-26 — — US disclosed
US-20110065737-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-03-17 — — US disclosed
US-20110033420-A1 MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-02-10 — — US disclosed
US-20100120859-A1 NOVEL CASE OF RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2010-05-13 — — US disclosed
US-20090286814-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-11-19 — — US disclosed
EP-1399436-B1 OXYTOCIN AGONISTS FERRING BV (NL) 2005-03-16 — — EP disclosed
US-20040235753-A1 Oxytocin agonists PITT GRAY ROBERT WILLIAM (GB) 2004-11-25 — — US disclosed
EP-1399436-A2 OXYTOCIN AGONISTS Ferring BV (NL) 2004-03-24 — — EP disclosed
WO-2003000692-A2 OXYTOCIN AGONISTS FERRING BV (NL) 2003-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12084429-B2 Fused ring compounds KRAS, NRAS, HRAS CTSC 2543/4885CHRNB2 3939/4885CHRNA4 4710/4885
US-20040235753-A1 Oxytocin agonists OXTR, GNRHR, PRLHR CTSC 4338/4885CHRNB2 235/4885CHRNA4 210/4885
US-20110123496-A1 BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS PRSS1, CTSC, CES1 CTSC 2/4885CHRNB2 4880/4885CHRNA4 4774/4885
US-20250059163-A1 FUSED RING COMPOUNDS KRAS, NRAS, HRAS CTSC 2543/4885CHRNB2 3939/4885CHRNA4 4710/4885
US-20100120859-A1 NOVEL CASE OF RENIN INHIBITORS REN, ACE, AGTR1 CTSC 11/4885CHRNB2 4633/4885CHRNA4 4381/4885
US-20110065737-A1 HCV PROTEASE INHIBITORS RNASE1, HAVCR2, CTRL CTSC 4/4885CHRNB2 4883/4885CHRNA4 4882/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 CTSC 284/4885CHRNB2 3083/4885CHRNA4 3549/4885
US-20090286814-A1 HCV PROTEASE INHIBITORS HAVCR2, SPINT2, RNASE1 CTSC 4/4885CHRNB2 4881/4885CHRNA4 4882/4885
US-12325701-B2 YKL-40 inhibitors and their therapeutic CHI3L1, CHI3L2, CHIA CTSC 96/4885CHRNB2 4228/4885CHRNA4 4652/4885
US-20110033420-A1 MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS CTSC, HAVCR2, DPP4 CTSC 1/4885CHRNB2 4885/4885CHRNA4 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.